Establishing biomarkers for COVID-19 that indicate which patients are likely to develop severe disease could help clinicians to categorize patients earlier, improve prognosis and prioritize treatment.
Click here to find out more about Abcam’s SimpleStep ELISA® for blood biomarkers.
Multiplicom is proud to launch Clarigo™, a new CE-IVD1 non-invasive prenatal test (NIPT). This highly accurate blood test will enable genetic analysis laboratories to detect the presence or absence of major chromosomal abnormalities such as trisomy 21 (Down’s syndrome), 18 (Edwards’ syndrome) and 13 (Patau syndrome), in the fetus, as early as in the first trimester of pregnancy by analysis of the fetus’s DNA in the maternal blood.
October 22, 2015 More +
Gaining an understanding of the molecular mechanisms that govern ovarian cancer detection and progression is crucial to increased survival rates for this disease.
August 23, 2018 More +
Call us on: + 961 1 39 66 77
